Paratek Pharmaceuticals (PRTK): Analyst Day Takeaways - Baird

November 18, 2016 6:48 AM EST
Get Alerts PRTK Hot Sheet
Price: $13.40 +0.37%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade PRTK Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Baird analyst, Michael Ulz, reiterated his Outperform rating on shares of Paratek Pharmaceuticals (NASDAQ: PRTK) after an analyst day focused on omadacycline’s promising profile and encouraging value proposition.

Data from the OASIS study were highlighted along with notable updates from a number of Phase 1 studies that provided proof-of-principal in UTI and increased the analyst's confidence in CABP.

The analyst continues to believe omadacycline is underappreciated with what is expected to be a transformational 2017 (Phase 3 data from oral-only ABSSSI 2Q17 and CABP 3Q17).

No change to the price target of $40.

For an analyst ratings summary and ratings history on Paratek Pharmaceuticals click here. For more ratings news on Paratek Pharmaceuticals click here.

Shares of Paratek Pharmaceuticals closed at $13.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Comments

Related Entities

Robert W Baird

Add Your Comment